返回 Agenda
Session Chair(s)
Jan Kevin Losos, PHD
Director, Safety Assessment Projects
GlaxoSmithKline, United States
Imran Khan, PHD
Pharmacologist, OMPT, OND, ODEI, DPP, CDER
FDA, United States
Speaker(s)
Glomerular Effects of Antisense Oligonucleotide Therapies and their Potential Mechanism
Kendall Frazier, DVM, PHD
Retired, United States
A Novel Antisense Oligo Targeting SGLT2 in the Kidney: Twists and Turns In Preclinical Development
Thomas Zanardi, PHD
Isis Pharmaceuticals, Inc., United States
Director, Toxicology
Renal Effects and Clinical Monitoring of Drisapersen
Kevin E. Meyers
Perelman School of Medicine at the Univ. of Pennsylvania, United States
Assistant Chief, Division of Nephrology